7c0ac3860a1ff04bf3ec9d6476e75d41

1. GENETISURE DX POSTNATAL ASSAY (GENITISURE DX ENSAYO POSTNATAL)

GENCELL PHARMA SAS·II·Colombia INVIMA·Expires March 12, 2034

Device classification

Risk class / Clase de Riesgo: II
Product type (Spanish): REACTIVO DIAGNOSTICO
Product type (English): DIAGNOSTIC REAGENT

Registration information

Analysis ID: 7c0ac3860a1ff04bf3ec9d6476e75d41
Expire date: March 12, 2034

Authorized company / Fabricante

Name (Spanish): GENCELL PHARMA SAS
Name (English): GENCELL PHARMA SAS

Product use / Uso del Producto

Spanish

DETERMINACIÓN DE LOS DIFERENTES ANALITOS RELACIONADOS CON MUESTRAS PROCEDENTES DEL ORGANISMO HUMANO

English

DETERMINATION OF THE DIFFERENT ANALYTES RELATED TO SAMPLES FROM THE HUMAN ORGANISM

About this record

Access comprehensive regulatory information for 1. GENETISURE DX POSTNATAL ASSAY (GENITISURE DX ENSAYO POSTNATAL) (1. GENETISURE DX POSTNATAL ASSAY (GENITISURE DX ENSAYO POSTNATAL)) in the Colombia medical device market through Pure Global AI's free database. This II medical device is registered under INVIMA analysis ID 7c0ac3860a1ff04bf3ec9d6476e75d41 and manufactured by GENCELL PHARMA SAS. The device was registered on March 12, 2034.

This page provides complete registration details including product type (DIAGNOSTIC REAGENT), authorised information, and regulatory compliance data from the official Colombia INVIMA medical device database. Pure Global AI offers free access to Colombia's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate INVIMA regulations efficiently.